The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Can stereotactic ablative radiotherapy for oligometastatic pancreatic cancer help avoid perpetual chemotherapy and improve outcomes?
 
Ahmed Elamir
No Relationships to Disclose
 
John D Karalis
No Relationships to Disclose
 
Nina Niu Sanford
No Relationships to Disclose
 
Patricio Polanco
No Relationships to Disclose
 
Matthew R. Porembka
No Relationships to Disclose
 
Robert D. Timmerman
Research Funding - Accuray (Inst); Elekta (Inst); Varian Medical Systems (Inst)
 
Matteo Ligorio
Patents, Royalties, Other Intellectual Property - Patent number: US9301926 B2
Other Relationship - Ligorio-Napier
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Cancer Commons; Foundation Medicine; Ipsen; Legend Biotech
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Todd Anthony Aguilera
Stock and Other Ownership Interests - AKSO Biopharmaceutical; Avelas Biosciences
Consulting or Advisory Role - Apexigen
Research Funding - Apexigen (Inst); Galera Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent from Stanford with royalties for licensing to Akso Biosciences; Patent from UCSD with royalties for licensing to Avelas Biosciences